June 8, 2022 Twitter Claims Enforcement Increasing Takeaway - Claims made on social are top of FDA’s mind
June 1, 2022 FDA Crackdown on CBD in Animal Products Takeaway - Product review engagement leads to a warning letter
May 25, 2022 Disease Claims Turn Supplements Into Unapproved New Drugs Takeaway - Screen all blogs and social media for disease claims
May 18, 2022 GMP Violations & Unanswered 483s Lead to a Warning Letter Takeaway - Ensure 483 responses are complete
May 11, 2022 10 Companies Cited for NDIs and Impermissible Ingredients Takeaway - Supplement should contain safe ingredients
May 4, 2022 CBD Company Cited For Claims Made in Blogs and Socials Takeaway - Blogs on a commercial website are marketing claims
April 27, 2022 Product Tags & Metatags Attract FDA Attention Takeaway - Everything used to market products must be compliant
April 20, 2022 Best Practices For Reducing Risk in Blogs Takeaway - Blogs can easily cross the line from “education” to “disease claims”
April 13, 2022 LinkedIn Posts Mentioned in Warning Letter Takeaway - All social media is “fair game” for enforcement
April 6, 2022 6-Year-Old Social Media Posts & Hashtags in Warning Letter Takeaway - Uncompliant hashtags attract FDA attention
March 30, 2022 7 CBD Companies Cited for Implied COVID claims Takeaway - Citing clinical studies on a commercial website is high risk